Expertise in
6
conditions

Dr. Meghann P. Mcmanus

Hematology | Oncology
TriStar Medical Group Children's Specialists
330 23rd Ave N Ste 100, 
Nashville, TN 
Clinical Trials:Currently Recruiting for 4 Trials
Accepting New Patients
Expertise in
6
conditions
TriStar Medical Group Children's Specialists
330 23rd Ave N Ste 100, 
Nashville, TN 

Overview

Meghann Mcmanus is a Hematologist and an Oncologist practicing medicine in Nashville, Tennessee.

Dr. Mcmanus is highly rated in 6 conditions, according to our data. Her clinical expertise encompasses Beta Thalassemia, Niemann-Pick Disease, Polycystic Lipomembranous Osteodysplasia with Sclerosing Leukoencephalopathy, Bone Marrow Aspiration, and Bone Marrow Transplant.

She is actively involved in clinical research, co-authoring 11 peer reviewed articles and participating in 20 clinical trials. Dr. Mcmanus is currently accepting new patients.

Specialties

Hematology
Oncology

Licenses

Pediatric Hematology-Oncology in UT

Hospital Affiliations

Tristar Centennial Medical Center

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Oscar
  • EPO
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 7 Less Insurance Carriers -

Locations

TriStar Medical Group Children's Specialists
330 23rd Ave N Ste 100, Nashville, TN 37203

Additional Areas of Focus

Dr. Mcmanus has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Immune Thrombocytopenic Purpura (ITP)
Neurofibromatosis Type 1 (NF1)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

20 Clinical Trials

The Project: EveryChild Protocol: A Registry, Eligibility Screening, Biology and Outcome Study
The Project: EveryChild Protocol: A Registry, Eligibility Screening, Biology and Outcome Study
Enrollment Status: Recruiting
Publish Date: August 25, 2026
Intervention Type: Other
A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients With Germ Cell Tumors
A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients With Germ Cell Tumors
Enrollment Status: Recruiting
Publish Date: August 25, 2026
Intervention Type: Procedure, Biological, Drug, Other
Study Drugs: Bleomycin, Bleomycin Sulfate, Carboplatin, Cisplatin, Etoposide, Etoposide Phosphate
Study Phase: Phase 3
Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) and Relapsed Favorable Histology Wilms Tumors (FHWT)
Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) and Relapsed Favorable Histology Wilms Tumors (FHWT)
Enrollment Status: Recruiting
Publish Date: August 25, 2026
Intervention Type: Radiation, Drug, Procedure
Study Drugs: Carboplatin, Cyclophosphamide, Doxorubicin, Etoposide, Ifosfamide, Irinotecan, Topotecan, Vincristine
Study Phase: Phase 2
A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494, NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy
A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494, NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy
Enrollment Status: Recruiting
Publish Date: August 25, 2026
Intervention Type: Procedure, Drug, Biological, Radiation, Other
Study Drugs: Calaspargase, Cyclophosphamide, Cytarabine, Daunorubicin, Dexamethasone, Doxorubicin, Inotuzumab, Leucovorin, 6-Mercaptopurine, Methotrexate, Pegaspargase, Prednisolone, Thioguanine, Vincristine
Study Phase: Phase 3
A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating With Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864) in Patients With Intermediate Risk (IR) Rhabdomyosarcoma (RMS)
A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating With Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864) in Patients With Intermediate Risk (IR) Rhabdomyosarcoma (RMS)
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Radiation, Drug, Biological, Other
Study Drugs: Cyclophosphamide, Dactinomycin, Irinotecan hydrochloride, Temsirolimus, Vincristine sulfate, Vinorelbine
Study Phase: Phase 3
Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients With Non-High-Risk Neuroblastoma
Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients With Non-High-Risk Neuroblastoma
Enrollment Status: Active_not_recruiting
Publish Date: August 25, 2026
Intervention Type: Drug, Procedure, Other
Study Drugs: Carboplatin, Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide
Study Phase: Phase 3
International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Testing Imatinib in Combination With Two Different Cytotoxic Chemotherapy Backbones
International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Testing Imatinib in Combination With Two Different Cytotoxic Chemotherapy Backbones
Enrollment Status: Active_not_recruiting
Publish Date: August 19, 2026
Intervention Type: Drug, Procedure, Other, Biological
Study Drugs: Cyclophosphamide, Cytarabine, Daunorubicin Hydrochloride, Dexamethasone, Dexrazoxane Hydrochloride, Doxorubicin, Etoposide, Filgrastim, Ifosfamide, Imatinib Mesylate, Leucovorin Calcium, Mercaptopurine, Methotrexate, Methylprednisolone, Pegaspargase, Prednisolone, Hydrocortisone, Thioguanine, Vincristine Sulfate
Study Phase: Phase 3
Risk-Stratified Therapy for Acute Myeloid Leukemia in Down Syndrome
Risk-Stratified Therapy for Acute Myeloid Leukemia in Down Syndrome
Enrollment Status: Active_not_recruiting
Publish Date: August 19, 2026
Intervention Type: Drug, Other
Study Drugs: Asparaginase, Erwinia Asparaginase, Cytarabine, Daunorubicin, Etoposide, Mitoxantrone, Thioguanine
Study Phase: Phase 3
A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: August 04, 2026
Intervention Type: Drug, Biological, Procedure, Other, Radiation
Study Drugs: Brentuximab, Dacarbazine, Doxorubicin, Filgrastim, Nivolumab, Pegfilgrastim, Vinblastine
Study Phase: Phase 3
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of LOXO-292 in Patients With Tumors Harboring RET Gene Alterations
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of LOXO-292 in Patients With Tumors Harboring RET Gene Alterations
Enrollment Status: Active_not_recruiting
Publish Date: August 03, 2026
Intervention Type: Procedure, Drug
Study Drug: Selpercatinib
Study Phase: Phase 2
View 6 Less Clinical Trials

11 Total Publications

Incidence of Human Leukocyte Antigen (HLA) Class I Antibodies and Impact on Platelet Engraftment, Transfusions and Bleeding in Recipients of Gene Therapy for Sickle Cell Disease and Transfusion Dependent Beta Thalassemia.
Incidence of Human Leukocyte Antigen (HLA) Class I Antibodies and Impact on Platelet Engraftment, Transfusions and Bleeding in Recipients of Gene Therapy for Sickle Cell Disease and Transfusion Dependent Beta Thalassemia.
Journal: Transplantation and cellular therapy
Published: July 02, 2026
Similar Doctors
Expertise in
5
conditions
Dr. Michael R. Debaun
Hematology | Oncology
Expertise in
5
conditions
Dr. Michael R. Debaun
Hematology | Oncology
Referral may be required

Vanderbilt Children's Hematology-Oncology

2200 Childrens Way # 6, 
Nashville, TN 
 (1.2 miles away)
615-322-5000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Michael Debaun is a Hematologist and an Oncologist practicing medicine in Nashville, Tennessee. Dr. Debaun is highly rated in 5 conditions, according to our data. His clinical expertise encompasses Sickle Cell Disease, Congenital Hemolytic Anemia, Hemoglobinopathy, Hemolytic Anemia, and Bone Marrow Transplant. Dr. Debaun is currently accepting new patients.

Expertise in
6
conditions
Dr. Carrie L. Kitko
Hematology | Oncology
Expertise in
6
conditions
Dr. Carrie L. Kitko
Hematology | Oncology
Referral may be required

Office

2200 Childrens Way Fl 6, 
Nashville, TN 
 (1.2 miles away)
615-322-5000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Carrie Kitko is a Hematologist and an Oncologist practicing medicine in Nashville, Tennessee. Dr. Kitko is highly rated in 6 conditions, according to our data. Her clinical expertise encompasses Graft Versus Host Disease (GvHD), Chronic Graft Versus Host Disease (cGvHD), Febrile Neutropenia, Acute Lymphoblastic Leukemia (ALL), and Bone Marrow Transplant. Dr. Kitko is currently accepting new patients.

Expertise in
39
conditions
Expertise in
39
conditions
Referral may be required

Tennessee Oncology, PLLC-#412 25th Ave

250 25th Ave N, Ste 412, 
Nashville, TN 
 (1.2 miles away)
615-986-7600
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Ian Flinn is an Oncologist practicing medicine in Nashville, Tennessee. Dr. Flinn is highly rated in 39 conditions, according to our data. His clinical expertise encompasses Small Lymphocytic Lymphoma (SLL), Chronic Lymphocytic Leukemia (CLL), Chronic B-Cell Leukemia (CBCL), Non-Hodgkin Lymphoma, and Bone Marrow Aspiration. Dr. Flinn is board certified in The American Board Of Internal Medicine - Hematology. Dr. Flinn is currently accepting new patients.

Frequently Asked Questions about Dr. Meghann P. Mcmanus

Is Dr. Meghann P. Mcmanus a top-rated expert for Beta Thalassemia?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Meghann P. Mcmanus is classified as an Advanced expert for Beta Thalassemia, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Meghann P. Mcmanus specialize in?

While Dr. Meghann P. Mcmanus is a Hematology, they have specific expertise in Beta Thalassemia, Niemann-Pick Disease, and Polycystic Lipomembranous Osteodysplasia with Sclerosing Leukoencephalopathy. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Meghann P. Mcmanus participate in research or clinical trials?

Yes. Dr. Meghann P. Mcmanus has published 11 articles and abstracts on conditions like Beta Thalassemia. You can view a list of Dr. Meghann P. Mcmanus's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Meghann P. Mcmanus accept my insurance?

Dr. Meghann P. Mcmanus accepts most major insurance plans, including Aetna and Blue Cross Blue Shield. We recommend calling the office directly to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Mcmanus's expertise for a condition
ConditionClose
      View All 59 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile